- Home
- PETS vs CUE Comparison
PETS vs CUE Comparison
Compare PETS & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | CUE |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 49.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PETS | CUE |
|---|---|---|
| Price | $1.61 | $0.54 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $3.20 | $3.00 |
| AVG Volume (30 Days) | 225.0K | ★ 361.2K |
| Earning Date | 02-02-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $226,972,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | $36.58 |
| Revenue Next Year | $2.98 | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.59 | $0.53 |
| 52 Week High | $6.85 | $1.75 |
Technical Indicators
Market Signals| Indicator | PETS | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 31.63 | 31.22 |
| Support Level | $1.69 | $0.55 |
| Resistance Level | $1.83 | $0.66 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 11.25 | 7.55 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.